Cigna Dips, Humana Rises Amid Revived Merger Discussions: Retail Sentiment Divided

Cigna and Humana held talks to merge last year as well, but Cigna walked away after failing to agree on a price.
Cigna headquarters in Bloomfield, Connecticut | Source: Cigna
Cigna headquarters in Bloomfield, Connecticut | Source: Cigna
Profile Image
Prabhjote Gill·Stocktwits
Updated Jul 02, 2025   |   8:31 PM GMT-04
Share
·
Add us onAdd us on Google

Cigna ($CI) shares slid 4%, while Humana ($HUM) gained as much as 5% pre-market on Monday amid reports that the two companies have revived merger discussions.

The health insurance companies, with a combined market value exceeding $125 billion, have recently held informal discussions about a potential merger after talks fell apart late last year, according to Bloomberg.

These early-stage negotiations are occurring against the backdrop of federal pressure to rein in Medicare costs, which have taken a toll on Humana’s financial stability and market position. The company’s stock has fallen 41% this year so far. 

Sources told Bloomberg that Cigna is looking to close the sale of its Medicare Advantage business in the coming weeks before committing to any other transactions. Cigna and Humana held talks to merge last year as well, but Cigna walked away after failing to agree on a price. 

Mizuho analyst Ann Hynes said that a merger could potentially lead to a Department of Justice (DOJ) lawsuit but it shouldn’t stop the deal from happening. The analyst highlighted that Humana’s buyout by Cigna is likely. “It’s just a matter of timing,” said the research note.

Screenshot 2024-10-21 092200.png
Cigna’s sentiment meter as of 9:00 a.m. ET on Oct. 21, 2024 | Source: Stocktwits

 

Screenshot 2024-10-21 092148.png
Humana's sentiment meter as of 9:00 a.m. ET on Oct. 21, 2024 | Source: Stocktwits

Retail sentiment around Cigna has flipped to ‘extremely bullish’ (87/100) from ‘bearish’ a day ago, while retail sentiment around Humana on Stocktwits continues to be ‘neutral’ (50/100). 

Users are divided on whether the deal will come through and whether Cigna returning to the table diminishes its negotiating power. 

Cigna’s stock has gained 4% so far in 2024, and 7% over the last 12 months. 

For updates and corrections email newsroom@stocktwits.com

Read More: BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed

Share
·
Add us onAdd us on Google
Read about our editorial guidelines and ethics policy